News | February 26, 2013

Sniffing Out the Side Effects of Radiotherapy May Soon Be Possible

February 26, 2013 — Researchers at the University of Warwick and The Royal Marsden NHS Foundation Trust have completed a clinical study that may lead to clinicians being able to more accurately predict which patients will suffer from the side effects of radiotherapy.

Gastrointestinal side effects are commonplace in radiotherapy patients and occasionally severe, yet there is no existing means of predicting which patients will suffer from them. The results of the pilot study, published in the journal Sensors, outline how the use of an electronic nose and a newer technology, FAIMS (field asymmetric ion mobility spectrometry) might help identify those at higher risk.

Warwick Medical School, working in collaboration with the School of Engineering and The Royal Marsden NHS Foundation Trust (led by Dr. J Andreyev), carried out a pilot study to look into the relationship between levels of toxicity in the gut and the likelihood of experiencing side effects.

Dr. Ramesh Arasaradnam, of Warwick Medical School and Gastroenterologist at University Hospitals Coventry and Warwickshire, outlines the results of the study. "In the simplest terms, we believe that patterns in toxicity levels arise from differences in a patient's gut microflora. By using this technology we can analyze stool samples and sniff out the chemicals that are produced by these microflora to better predict the risk of side effects."

The success of the pilot study will lead to a broader investigation into the possible uses of these technologies and could be truly significant in helping clinicians inform patients receiving pelvic radiotherapy, before treatment is started.

Arasaradnam explains what this could mean for radiotherapy patients, "In essence, we will be able to predict those who are likely to develop severe gut related side effects by the pattern of gut fermentation that are altered as a result of radiotherapy. This will enable future directed therapy in these high risk groups."

Dr. James Covington, from the Warwick School of Engineering adds, "This technology offers considerable opportunities for the future. This shows just one application of being able to inform treatment by 'sniffing' patients. We foresee a time when such technology will become as routine a diagnostic test as checking blood pressure is today."

It is further evidence of the ongoing collaboration between Warwick Medical School and School of Engineering. This technology, first developed at Warwick in the early 1990s has been in continuous development ever since, producing some of the most sophisticated chemical sensors and sensor systems available today.

In 2009, the same high tech gas sensor was taken from the automotive world and used to research into quicker diagnosis for some gastrointestinal illnesses and metabolic diseases.

Related Content

Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
brain with chronic traumatic injury
News | Magnetic Resonance Imaging (MRI) | August 02, 2017
Fighters are exposed to repeated mild traumatic brain injury (mTBI), which has been associated with neurodegenerative...
Overlay Init